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R ecent genetic evidence supports a link between microglia and the complement system in Alzheimer’s disease (AD). In this
study, we uncovered a novel role for the microglial complement receptor 3 (CR3) in the regulation of soluble β-amyloid (Aβ)
clearance independent of phagocytosis. Unexpectedly, ablation of CR3 in human amyloid precursor protein–transgenic mice
results in decreased, rather than increased, Aβ accumulation. In line with these findings, cultured microglia lacking CR3 are
more efficient than wild-type cells at degrading extracellular Aβ by secreting enzymatic factors, including tissue plasminogen
activator. Furthermore, a small molecule modulator of CR3 reduces soluble Aβ levels and Aβ half-life in brain interstitial fluid
(ISF), as measured by in vivo microdialysis. These results suggest that CR3 limits Aβ clearance from the ISF, illustrating a novel
role for CR3 and microglia in brain Aβ metabolism and defining a potential new therapeutic target in AD.
Introduction
Aberrant accumulation of the β-amyloid (Aβ) peptide in the
brain parenchyma is widely hypothesized to initiate a pathogenic cascade leading to neuronal dysfunction and subsequent
cognitive decline in Alzheimer’s disease (AD; Hardy and
Selkoe, 2002). The factors that underlie Aβ accumulation in
sporadic AD are poorly understood. However, evidence indicates that impaired clearance is mainly responsible (Bateman
et al., 2006; Roberts et al., 2014). Clearance of soluble Aβ is
achieved by several mechanisms, including blood–brain barrier (BBB)–mediated transport, interstitial fluid (ISF) bulk
flow, and cellular uptake and degradation. Disturbances in any
of these pathways are likely to contribute to the development of Aβ accumulation. Removal of Aβ deposits is, in part,
mediated through phagocytic cells in concert with immune
recognition molecules (Lucin and Wyss-Coray, 2009; Czirr
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and Wyss-Coray, 2012). Indeed, microglia are now widely
recognized to have important roles in neurodegeneration
and in AD (Saijo and Glass, 2011). This notion has received
genetic support from genome-wide association studies that
have identified several single nucleotide polymorphisms in
immune-related genes that increase the risk of developing
late onset AD (Lambert et al., 2009; Jun et al., 2010; Naj et al.,
2011; Guerreiro et al., 2013; Jonsson et al., 2013). In the brain,
most of these genes are exclusively expressed in microglia,
highlighting their importance in AD. Complement receptor 3 (CR3; CR3, CD11b/CD18, and Mac-1) is one of the
major phagocytic receptors expressed on microglia (Ehlers,
2000) and is a dimeric receptor comprised of CD18 and its
unique subunit CD11b (Ivashkiv, 2009; Linnartz and Neumann, 2013).The receptor is able to mediate Aβ phagocytosis
(Fu et al., 2012), as well as the removal of synapses during
development (Stevens et al., 2007; Schafer et al., 2012), in
a model of neurodegeneration (Stevens et al., 2007) and in
amyloid precursor protein (APP)–transgenic mice (Hong et
al., 2016). Interestingly, levels of natural CR3 ligands, such as
complement fragments, ICAM-1, and fibrin, are increased in
AD patients (Shen et al., 2001; van Oijen et al., 2005; Ray et
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Figure 1. Lack of CR3 results in reduced
plaque deposition in APP transgenic mice
while leaving APP expression and processing unaffected. (A–D) Aβ staining in cortex
(A) and hippocampus (B) of APP and APP/
CR3−/− mice and quantification of Aβ immunoreactivity in cortex (C) and hippocampus (D).
12-mo-old mice were used. n = 8–9 mice per
group and 6 sections per mouse. *, P < 0.05.
Bars, 200 µm. (E and G) Western blots of cortical (E) and hippocampal (G) lysates showing full-length APP (flAPP) and C99 and C83
cleavage products, as well as β-actin and neuron-specific enolase (NSE) loading controls.
(F and H) Quantification of Western blots in
cortex (F) and hippocampus (H). (E–H) 3-moold male and female mice were used. n = 5
mice per group. Unpaired Student’s t test was
used. All values are mean ± SEM.

al., 2007; Xu et al., 2008; Ryu and McLarnon, 2009; Daborg
et al., 2012; Bardehle et al., 2015).
Here, we identify a novel role for microglia and
CR3 in the maintenance of Aβ homeostasis independent
of phagocytosis. In the absence of CR3, Aβ deposition is
reduced, and extracellular Aβ degradation is increased.
Furthermore, modulating CR3 with the small molecule
Leukadherin 1 (LA-1) increases Aβ degradation in vitro
while reducing ISF Aβ levels and half-life in vivo. Together,
these findings suggest that CR3 and microglia play an important role in Aβ homeostasis and identify a potential new
therapeutic target in AD.
Results
Genetic ablation of CR3 in APP-transgenic mice leads
to reduced Aβ deposition
Human AD brains show an increase in complement proteins associated with plaques (Afagh et al., 1996; Yasojima
1082

et al., 1999). Complement proteins are important for removal of Aβ deposits, and interference with the central
component C3 results in increased plaque deposition
(Wyss-Coray et al., 2002; Maier et al., 2008). Microglial
CR3 can target these deposits, and we initially hypothesized that lack of CR3 would result in higher Aβ plaque
load because of reduced phagocytic activity. To test this
hypothesis, we crossed mice deficient in its unique component CD11b (CR3−/−; Soriano et al., 1999) with APP
transgenic mice harboring two familial AD-associated
APP mutations (Rockenstein et al., 2001). Surprisingly,
the amount of Aβ deposition was decreased in 12-mo-old
APP mice lacking CR3 (Fig. 1, A and B). Quantification
of the percent Aβ-positive area showed a statistically significant decrease in plaque deposition in the hippocampus
(Fig. 1 D) and a trend in the same direction in the cortex
(Fig. 1 C), whereas expression of APP and its processing
were unaffected (Fig. 1, E–H).
Complement receptor 3 regulates brain Aβ turnover | Czirr et al.

Figure 2. CR3 deficiency leads to reduced phagocytic activity and increased Aβ degradation in vitro. (A and B) Western blot (A) and flow cytometric
quantification (B) of CD11b expression in CR3kd and control BV2 cell lines. (B) n = 2 replicates. (C and D) Quantification of baseline phagocytosis activity (C)
and phagocytosis efficiency (D) in control and CR3kd BV2 cells. (E) Schematic of Aβ degradation assay. (F and G) Cell-based (F) and cell-free (G) Aβ degradation assays of control and CR3kd cells were quantified. (H and I) Aβ degradation using primary adult microglia. (J and K) Aβ staining in hippocampus of mice
stereotactically injected with Aβ42 (J) and quantification of residual immunoreactivity (K). 3–4-mo-old male and female mice were used. n = 9 per group.
Bar, 200 µm. (C, D, and F–I) Representative graphs of three to five independent experiments are shown. Student’s t test (B, C, H, and K), two-way ANOVA
and Sidak’s posthoc test (D), or one-way ANOVA with Tukey’s posthoc test (F, G, and I) were used. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
All values are mean ± SEM.

Microglia lacking CR3 are more efficient
in degrading extracellular Aβ
In the brain, CR3 is exclusively expressed on microglia, allowing us to interpret changes in Aβ deposition in the context of microglia-dependent mechanisms. To study these
mechanisms in a myeloid cell model system, we generated
a stable CR3 knockdown BV2 cell line (CR3kd) and confirmed knockdown efficiency by Western blotting and flow
cytometric analysis of CD11b expression (Fig. 2, A and B).
First, we assessed the possibility that changes in phagocytosis
are responsible for the decrease in plaque accumulation by
measuring phagocytic activity of CR3kd cells. In agreement
with published data (Fu et al., 2012), we found a significant
decrease in baseline phagocytosis (Fig. 2 C) and phagocytic
efficiency (Fig. 2 D) in CR3-deficient cells.
JEM Vol. 214, No. 4

BV2 cells secrete several enzymes capable of degrading
extracellular Aβ (Qiu et al., 1997). We established an in vitro
Aβ degradation assay (Fig. 2 E) by adding freshly solubilized Aβ42 to serum-free medium on control or CR3kd cells
and collecting the conditioned medium for ELISA measurements at different time points. Aβ was removed more
rapidly from the supernatant of CR3kd than control cells
(Fig. 2 F). Interestingly, this effect was also present in a cellfree system where Aβ42 peptide was added to conditioned
medium alone (Fig. 2 G). We confirmed these findings
using cultured primary microglia isolated from adult WT
and CR3−/− mice. CR3−/− microglia and their supernatant
showed increased activity in the cell-based and the cell-free
Aβ degradation assay compared with microglia from WT
mice (Fig. 2, H and I).
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To test in vivo whether degradation of exogenously
added Aβ is enhanced in CR3−/− mice, we injected preaggregated Aβ42 stereotactically into the hippocampus of WT and
CR3−/− animals and quantified residual Aβ immunoreactivity
after 5 d. Aβ was removed more rapidly from the hippocampus of CR3−/− mice than WT mice (Fig. 2, J and K).
Collectively, our findings indicate that CR3-deficient
microglia and microglia-like cells are more efficient in removing stereotactically injected Aβ in vivo and soluble Aβ
in vitro, respectively.
CR3 deficiency results in increased secretion
of Aβ-degrading enzymes
To determine whether proteases mediate the increase in
Aβ-degrading activity, we added various protease inhibitors
in the cell-free Aβ degradation assay (Fig. S1, A and B). Then,
we evaluated how they affected the Aβ degradation ratio between conditioned supernatants of cultured primary adult
microglia isolated from WT and CR3−/− mice. A complete
protease inhibitor cocktail lacking EDTA and captopril, an
angiotensin-converting enzyme inhibitor, had no effect on
Aβ degradation (Fig. 3 A). However, several other inhibitors lessened the Aβ-degrading activity significantly. The
neprilysin inhibitor thiorphan reduced the degrading activity slightly, suggesting some involvement of neprilysin. The
most potent inhibitors were the complete protease inhibitor
cocktail containing EDTA, EDTA itself, and PMSF, a serine
protease inhibitor. EDTA is a strong inhibitor of metalloproteinases, and matrix metalloproteinase 2 (MMP2) and MMP9
have previously been implicated as major Aβ-degrading enzymes (Yan et al., 2006; Hernandez-Guillamon et al., 2010).
MMPs are regulated on the transcriptional and activity level,
leading us to quantify mRNA expression as well as protease
activity.We found mRNA expression of MMP2 and 9, as well
as of MMP8, 12, 13, and 14, unchanged between acutely isolated microglia from APP and APP/CR3−/− mice (Fig. 3 B
and Fig. S1 G). We also measured MMP activity using assays
for MMP2 and MMP9 activity, finding that overall MMP
activity and activity of specific MMPs were not significantly
changed in conditioned supernatant or cortical lysates from
CR3−/− mice (Fig. S1, C–F).
The serine protease inhibitor PMSF also showed strong
inhibition of the Aβ-degrading activity; one serine protease
that has been implicated in Aβ degradation is tissue plasminogen activator (tPA), which degrades Aβ via plasminogen activation (Melchor et al., 2003). Mice lacking tPA or plasminogen
are less efficient at degrading Aβ injected in the hippocampus
(Melchor et al., 2003), but the function of tPA in microglia
remains poorly understood (Tsirka et al., 1995; Gravanis and
Tsirka, 2005). tPA mRNA levels were unchanged between
acutely isolated primary adult microglia-like cells from APP
and APP/CR3−/− mice (Fig. 3 C). However, active tPA protein levels were significantly higher in conditioned medium
from CR3kd than from control cells (Fig. 3 D).Tissue zymography, which measures proteolytic activity ex vivo in tissue
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sections and, in the central nervous system, predominantly
detects tPA activity (Tsirka et al., 1995), revealed significantly
higher activity in APP/CR3−/− than in APP mice (Fig. 3, E
and F). Additionally, targeting tPA expression in CR3kd cells
by siRNA reduced the Aβ-degrading activity (Fig. 3 G) by
decreasing tPA mRNA levels (Fig. 3 H).
Together, these data suggest that tPA, as well as an
EDTA chelation-sensitive protease activity are responsible
for the enhanced Aβ degradation by CR3-deficient cells
and may account for the mechanism underlying the decreased Aβ deposition in vivo.
Targeting CR3 with the small molecule LA-1 results
in increased Aβ degradation in vitro
and reduced Aβ levels in vivo
Our data suggest that modulating CR3 could lead to enhanced Aβ clearance in the AD brain. Leukadherins are
small molecule modulators of CR3 function that bind to its
CD11b subunit, thereby increasing cell adhesion (Maiguel et
al., 2011). We found that treatment of BV2 cells with LA-1
resulted in a concentration-dependent increase in Aβ degradation (Fig. 4 A). This effect was absent in CR3kd cells
(Fig. 4 B), confirming that LA-1 requires the presence of
CR3. Consistent with these findings, young, preplaque APP
mice treated for 10 d with daily i.p. injections of LA-1 had
significantly reduced Aβ levels in the guanidine-extracted
fractions of the cortex and a trend toward a reduction in the
hippocampus compared with vehicle-treated mice (Fig. 4 C).
LA-1 did not change APP expression and processing in a
cell line, indicating that the drug reduces Aβ through other
mechanisms (Fig. S2, A–F).
Mass spectrometry analysis of whole-brain lysates from
mice treated with a single dose of LA-1 showed a spike in
LA-1 concentration 15 min after injection with detectable levels of the drug at the 2-h time point, demonstrating
BBB penetration (Fig. 4 D). Plasma levels also spiked at 15
min, but LA-1 was undetectable at 2 h after injection (Fig.
S2 H). Flow cytometric analysis of acutely isolated microglia and PBMCs revealed no changes in vascular adhesion
markers (Fig. S2, I and J).
Similar to microglia from CR3−/− mice, we did not
observe differences in MMP2 or MMP9 mRNA levels in
microglia from LA-1–treated mice (Fig. 4 F), nor in the expression of other MMPs (Fig. S2 G). However, we did find a
significant increase in tPA mRNA (Fig. 4 E), suggesting that
LA-1 may exert its function through tPA as well.
LA-1 treatment results in decreased ISF Aβ levels
and decreased ISF Aβ half-life
To directly monitor whether LA-1 treatment increases soluble Aβ clearance, we used in vivo microdialysis, which allows
measurement of soluble Aβ levels in the mouse ISF. We used
APP/PS1-ΔExon9–transgenic mice (Jankowsky et al., 2004),
which are routinely used for in vivo microdialysis (Yan et al.,
2009; Cramer et al., 2012; Kraft et al., 2013) at an age before
Complement receptor 3 regulates brain Aβ turnover | Czirr et al.

Figure 3. CR3-deficient cells and mice display increased tPA
activity. (A) Ratio of Aβ measured in conditioned medium from
CR3kd versus control BV2 cells after addition of proteinase inhibitors.
A representative graph of two independent experiments is shown. PI,
protease inhibitor; PI w/o, protease inhibitor cocktail lacking EDTA. (B
and C) qPCR analysis of mRNA from adult primary microglia, normalized to GAPDH. Microglia were from n = 7 individual mice. IDE, insulin-degrading enzyme; NEP, neprilysin. (D) Active tPA measurement in
conditioned medium from control and CR3kd cells. n = 2 independent
experiments. (E and F) Representative image of in situ zymography in
the hippocampus (E) and quantification of the lysed area (F). n = 5–6
mice. All mice were 3–4-mo-old males and females. Bar, 500 µm. (G)
Aβ degradation assay in control and CRkd cells transfected with control siRNA or tPA siRNA. (H) Knockdown efficiency was quantified by
qPCR. Data are combined from two independent experiments. Oneway ANOVA with Dunnett’s posthoc test and significance relative to
vehicle (A), unpaired Student’s t test (B, C, D, and F), or one-way ANO
VA with Tukey’s posthoc test (G and H) were used. *, P < 0.05; **, P <
0.01; ***, P < 0.001. All values are mean ± SEM.

Aβ deposition. Reverse microdialysis of LA-1 into the hippocampus significantly reduced steady-state Aβ levels in the ISF
(Fig. 5, A and B), consistent with our hypothesis. This effect
is reversible, as exchanging the drug for standard perfusion
buffer led to a rapid return to baseline steady-state Aβ levels
(Fig. 5, D and E).To measure the half-life of Aβ, its production
was stopped with the γ-secretase inhibitor Compound E, revealing that the rate of concentration decline was significantly
reduced in LA-1–treated mice (Fig. 5 C). We then repeated
these experiments using APP and APP/CR3−/− mice and
found that mice lacking CR3 did not show a reduction in ISF
Aβ levels below baseline after LA-1 treatment (Fig. 5, F and
G).These results indicate that CR3 expression is necessary for
LA-1–mediated enhancement of Aβ clearance. Collectively,
these data suggest that modulating CR3 with LA-1 reduces
brain Aβ levels by enhancing Aβ clearance from the ISF.
JEM Vol. 214, No. 4

Discussion
Despite advances in understanding the pathogenesis of AD,
little is known about the events initiating the accumulation of
Aβ in the brain and the contributions of the immune system. In
recent years, several studies have focused on the role of microglia in the pathogenesis of AD. Although microglia are able to
take up fibrillar Aβ into endosome-like compartments (Frackowiak et al., 1992; Meyer-Luehmann et al., 2008), they seem
inefficient at degrading and removing Aβ deposits from the AD
brain (Grathwohl et al., 2009). It has been suggested that the
proinflammatory environment of the AD brain might make
them less efficient phagocytes (Bamberger et al., 2003; Koenigsknecht-Talboo and Landreth, 2005).There is also evidence
that microglia internalize and degrade soluble Aβ in lysosomes
through fluid-phase macropinocytosis (Mandrekar et al., 2009)
or through the secretion of various Aβ-degrading activities.
1085

Figure 4. The small molecule modulator
LA-1 enhances Aβ degradation in vitro and
lowers Aβ levels in vivo. (A and B) Quantification of cell-based Aβ degradation assay
with LA-1 treatment in BV2 cells (A) and LA-1
treatment in control and CR3kd cell lines (B).
Representative graphs of two to three experiments are shown. (C) Aβ levels in guanidine-extracted fraction in APP mice after LA-1
treatment. n = 8–9 mice, male and female. CX
cortex, HC hippocampus. (D) Mass spectrometry quantification of brain levels of LA-1 after
single injection. n = 3 per time point, all male
mice. (E and F) qPCR analysis of mRNA from
primary microglia. n = 5 individual mice, male
and female. The dashed line shows the detection limit. (C–F) All mice were 3–4 mo old.
One-way ANOVA and Tukey’s posthoc test (A),
two-way ANOVA and Bonferroni posthoc test
(B), or unpaired Student’s t test (C, E, and F)
was used. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
All values are mean ± SEM.

Aβ degradation in the extracellular space can be accomplished by several enzymes, and published studies have mainly
focused on the proteases neprilysin,insulysin (insulin-degrading
enzyme), MMP2, MMP9, and tPA/plasmin (Iwata et al.,
2001; Melchor et al., 2003; Song and Hersh, 2005; Eckman
et al., 2006; Yan et al., 2006; Hernandez-Guillamon et al.,
2010). Our inhibitor screen suggests that neprilysin plays a
minor role in the increased Aβ degradation in our model,
and quantitative PCR (qPCR) on mRNA isolated from primary adult microglia did not show changes in neprilysin or
insulin-degrading enzyme expression. We did uncover an activity sensitive to EDTA chelation that is regulated by CR3,
but quantification of MMP activity and mRNA of several
MMPs failed to identify a specific isoform. It is possible that
our methods were not sensitive enough to measure the specific MMP activity or that a different, as yet unidentified,
EDTA-sensitive protease mediates this effect. However, we did
find increased levels of active tPA in vitro and in vivo under
CR3-deficient conditions. tPA has previously been described
as part of an important Aβ degradation pathway (Melchor
et al., 2003). It can activate both plasminogen and MMPs
and, therefore, mediate Aβ degradation via different pathways
(Hahn-Dantona et al., 1999; Ramos-DeSimone et al., 1999).
Additionally, tPA can bind LRP1 and could mediate efflux of
Aβ from the mouse brain by facilitating BBB transport (Su et
al., 2008).The fact that we found increased levels of active tPA
in vitro and in vivo identifies it as one of the likely mediators
of enhanced Aβ degradation in APP/CR3−/− mice.
The small molecule LA-1 was originally identified
through a screen searching for monocyte adhesion enhancers,
and it has been suggested that it mediates its effects by changing
the local conformation of the extracellular domain of CD11b
(Maiguel et al., 2011; Faridi et al., 2013). It has been used to
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anchor CR3-expressing cells in place and prevent infiltration
of proinflammatory monocytes after injury in peripheral organs (Maiguel et al., 2011; Jagarapu et al., 2015). However, the
effects of LA-1 on microglia have not been studied.We found
that LA-1 enhances extracellular Aβ degradation and that it
can lower Aβ levels in vivo by enhancing clearance from the
ISF. Furthermore, LA-1 treatment in mice results in increased
levels of tPA mRNA in acutely isolated microglia.
In summary, both lack of CR3 and treatment with
LA-1 lead to increased Aβ degradation in vitro, and LA-1
increases Aβ clearance in vivo. Furthermore, tPA activity was
increased in conditioned media of CR3kd cells and in APP/
CR3−/− brain tissue, and tPA mRNA levels were increased in
microglia isolated from LA-1–treated mice, suggesting at least
in part a similar mechanism. To date, little is known about the
effects of CR3 deficiency or LA-1 treatment in microglia
relating to the secretory or expression profiles. There is evidence from studies in human PBMC–derived macrophages,
human monocyte cell lines (Reed et al., 2013), and in human
NK cells (Roberts et al., 2016) that LA-1 treatment can affect
key transcription factors, e.g., MyD88, to modulate secretion
of cytokines. LA-1 might act as a partial antagonist, reducing
signaling that inhibits the secretion of Aβ-degrading enzymes,
although leaving other functions unaffected or even enhancing them (e.g., adhesion). Thus, LA-1 might mimic CR3 deficiency in some aspects but not in all microglial functions
and signaling pathways. Future studies will have to dissect
how LA-1 engages CR3 and how CR3 modulation results
in the release of an Aβ-degrading activity from microglia.
Our data indicate a novel function of the phagocytic receptor
CR3 in the suppression of microglia-mediated clearance of
soluble Aβ. Furthermore, targeting CR3 with a small molecule can reduce Aβ levels in brains of APP-transgenic mice by
Complement receptor 3 regulates brain Aβ turnover | Czirr et al.

Figure 5. LA-1 treatment decreases ISF Aβ concentration by enhancing clearance. (A) Time course of in vivo microdialysis. 8 h of baseline measurements, followed by LA-1 infusion for 16 h, and the last 4 h with additional infusion of Compound E. (B) Quantification of ISF Aβ concentrations after 6 h of
LA-1 infusion. (C) Quantification of Aβ half-life. (D) Time course of in vivo microdialysis. 8-h baseline measurements, followed by 4-h LA-1 infusion and 12-h
washout. (E) Quantification of D. (F) Time course of in vivo microdialysis in APP and APP/CR3−/− mice with 8 h of baseline, followed by 12 h of LA-1 infusion.
(G) Quantification of ISF Aβ concentration after 6 h of LA-1 infusion. n = 5 mice per group, male and female (A–C); n = 2 mice, all male (D and E); or APP, n =
2 and APP/CR3−/−, n = 5, male and female (F and G). Unpaired Student’s t test was used. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. All values are mean ± SEM.

enhancing Aβ clearance from the extracellular space. Therefore, CR3 may be a potential therapeutic target for the treatment or prevention of AD.
Materials and methods
Transgenic mice
T41 APP-transgenic mice (mThy-1-hAPP751V171I,KM670/671NL),
CR3-deficient mice (Itgamtm1Myd+/−), and APP/PS1+/−
(mPrP-hAPPKM670/671NL PS1-ΔExon9) mice have been described previously (Soriano et al., 1999; Rockenstein et al.,
2001; Savonenko et al., 2005). All lines were maintained on a
C57BL/6 genetic background.All animal procedures were conJEM Vol. 214, No. 4

ducted with approval of the Animal Care and Use Committee
of the Veterans Administration Palo Alto Health Care System.
Tissue collection and processing
Mice were anesthetized with 400 mg/kg chloral hydrate
(Sigma-Aldrich) and transcardially perfused with sterile PBS.
Brains were removed and divided saggitally. One hemibrain
was postfixed in phosphate-buffered 4% paraformaldehyde,
pH 7.4, at 4°C for 48 h, cryoprotected in 30% sucrose in PBS,
and sectioned at 35 µm with a freezing microtome (Leica
Biosystems). The other hemibrain was snap frozen and stored
at −80°C for further analysis.
1087

Immunohistochemistry and image analysis
Immunohistochemistry was performed on free-floating
sections according to standard procedures. In brief, fixed
sections were treated with 0.1% Triton X-100 and 0.6%
hydrogen peroxide and blocked using an avidin and biotin blocking kit (Vector Laboratories), followed by incubation with biotinylated 3D6 (Perrigo Company) antibody at
1:8,000 overnight at 4°C. Primary antibody labeling was
revealed using an ABC kit (Vector Laboratories) followed
by diaminobenzedine staining (Sigma-Aldrich). For the
transgenic animals, six sections separated by 480 µm were
analyzed per animal. After stereotactic injections, brains
were sectioned at 35 µm, and all sections surrounding the
injection site were collected (a minimum of 10 sections
to either side) and stained. Images were acquired using a
NanoZoomer slide scanner (Hamamatsu Photonics), and
immunoreactivity was quantified with ImageJ software
(National Institutes of Health) in a blinded fashion with a
fixed threshold for all sections. For the stereotactic injections, all immunoreactivity was added up and normalized to
WT levels independently for two experiments.
Drug treatment
LA-1–treated mice were injected for 10 d, daily, i.p. with
500 µl of 50 µM LA-1 (EMD Millipore) or DMSO vehicle in PBS. For reverse microdialysis, drugs were diluted in
microdialysis perfusion buffer. Compound E was purchased
from Sigma-Aldrich. Cells were incubated with LA-1 in vitro
at the indicated concentrations in serum-free culture medium
for 3–6 h. For assessment of APP processing in APP-overexpressing Chinese hamster ovary cells (Weggen et al., 2003),
lysates and supernatants were collected after 6 h.
Cell lines
BV2 cells were maintained in DMEM containing 10% FBS.
CR3 knockdown (CR3kd) cells were generated by transduction with a CD11b-targeting shRNA lentivirus carrying
a puromycin resistance cassette (OriGene) or empty vector control virus. Stable lines were selected with 5 µg/ml
puromycin. In addition to puromycin selection, knockdown
cell lines were maintained by sorting of CD11blow cells
from the mixed culture.
For siRNA-mediated transient knockdown, BV2 control and CR3kd cells were transiently transfected on day 1
using Viromer Blue reagent (Lipocalyx) and On-Target SMA
RT-pool siRNA-targeting mouse Plat (tPA; GE Healthcare)
expression and control siRNA (GE Healthcare) according to
the manufacturer’s instructions. After 48 h, cells were replated
and used for the in vitro Aβ degradation assay. siRNA pool
target sequences for Plat were: 5′-CGGCCUCAGUUUAGA
AUUA-3′, 5′-GAAGCAGCCGGGUGGAAUA-3′, 5′-GAA
AGCUGACGUGGGAAUA-3′, and 5′-AAAGUGGUC
UUGGGCAGAA-3′. Sequences for the control siRNA were
not provided by the manufacturer.
1088

Isolation of primary adult mouse microglia
Adult microglia were isolated using a neural dissociation kit
(Miltenyi Biotec) followed by magnetic-activated cell sorting
with CD45 micro beads (Miltenyi Biotec) according to the
manufacturer’s instructions. CD45 antibody–coupled beads
were used as a replacement for CD11b beads, as the receptor is
lacking in the CR3-deficient animals. In brief, perfused brains
of 3–4-mo-old mice were dissociated using the neuronal dissociation kit (Miltenyi Biotec), incubated with CD45 microbeads (Miltenyi Biotec), and separated using an LS separation
column (Miltenyi Biotec). For functional studies, the cells were
allowed to recover for 3 d in DMEM/F12 with 10% FBS.
Cells for RNA were immediately frozen at −80°C. Cells used
for flow cytometry were kept on ice and stained immediately.
In vivo microdialysis and
quantitative measurement of ISF Aβ
In vivo microdialysis was performed as previously described
(Cirrito et al., 2003; Castellano et al., 2011). In brief, microdialysis guide cannula and probes with a 38-kD molecular weight cutoff membrane (BR-2 probes; Bioanalytical
Systems) were inserted into the left hippocampus at the
following coordinates: bregma, −3.1 mm; midline, −2.5
mm; and tip, 3.2 mm below dura at a 12° angle. Perfusion
buffer (0.15% BSA in artificial cerebrospinal fluid [in mM:
1.3 CaCl, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25 NaHCO3,
and 122 NaCl, pH 7.35]) was perfused at a 1-µl/min flow
rate with a syringe pump (Stoelting Co). Microdialysis
samples were collected every 60–90 min using a refrigerated fraction collector (Univentor). Mice were housed in
a RaTurn Caging system (Bioanalytical Systems) with ad
libitum food and water for the duration of the experiment. LA-1 and Compound E (AsisChem) were perfused
directly into the hippocampus through the microdialysis
probe (reverse microdialysis) at a concentration of 100 µM
and 200 nM, respectively.
Quantitative measurements of Aβ collected from in vivo
microdialysis fractions were performed by sandwich ELISA,
as previously described (Cirrito et al., 2011). ELISA plates
were coated with a mouse anti-Aβ40 selective antibody, mHJ2,
and detected with a biotinylated central domain mouse antiAβ (amino acids 13–28) antibody, mHJ5.1.
Aβ degradation assay
For the cell-based degradation assay, BV2 cells or primary
microglia were plated at 250,000 cells per well on 24-well
plates and allowed to attach overnight.The next morning, the
medium was exchanged for serum-free DMEM containing
1 µg/ml freshly solubilized Aβ1-42 peptide (Bachem). For
treatment with LA-1 or vehicle, serum-free DMEM containing LA-1 or vehicle was added to the cells 30 min before Aβ1-42 was added at 1 µg/ml. For the cell-free assay,
serum-free DMEM was conditioned for 16–18 h for BV2
cells and for 48 h for primary microglia at the same cell density.The supernatant was centrifuged at 1,000 g for 15 min to
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remove cells and debris and transferred into a fresh tube. Aβ142 was added at 1 µg/ml to the conditioned supernatants and
incubated. For both assays, samples were taken at defined time
points and transferred into a tube containing complete protease inhibitor cocktail (Roche) to a final concentration of 2×.

in the tissue culture incubator and subsequently transferred to
5 ml polystyrene FACS tubes with the aid of TrypLE Express
reagent (Thermo Fisher Scientific). Cells were washed twice
with cold FACS buffer (1% FBS and 0.02% sodium azide in
PBS) and then analyzed by flow cytometry.

Aβ ELISA and tissue preparation
ELISAs were performed using Meso Scale technology (Meso
Scale Discovery). Multiarray 96-well plates (Meso Scale Discovery) were coated with capture antibody 21D12 for total
Aβ (Aβ12-28; Elan Pharmaceuticals). Plates were washed, and
diluted samples or Aβ1-40 peptide standards were added. Aβ
was detected using biotinylated 3D6 antibody (Elan Pharmaceuticals) and SULFO-TAG streptavidin (Meso Scale Discovery). Plates were read on a Sector Imager 2400 (Meso Scale
Discovery), and samples were normalized to Aβ standards.
Mouse tissue was subjected to serial Aβ extraction using
PBS, RIPA (50 mM Tris-HCl, pH 7.4, 150 mM sodium chloride, 1% Nonidet P40, 1 mM EDTA, and 0.25 deoxycholic
acid), and guanidine buffer (5 M guanidine-HCl in 50 mM
Tris-HCl), with all buffers containing complete protease inhibitor cocktail (Roche) at a concentration of 2×.

RNA extraction and real-time PCR
RNA was extracted using the RNeasy kit (QIAGEN) according to the manufacturer’s instructions. 100 ng of extracted microglial mRNA was reverse transcribed using the SuperScript
III first strand synthesis system (Thermo Fisher Scientific).
Gene expression was assessed using intron-spanning primers
(for sequences, see Table S1), and GAPDH was used as the
housekeeping gene. 1:20 diluted cDNAs were mixed with
the probes and 2× LightCycler 480 SYBR Green I Master
mix (Roche) and amplified using a Roche Light Cycler 480
(Roche). Results were analyzed using the ΔΔCt method.

Gelatinase and MMP activity assays
Activity of gelatinase and MMPs was measured using the
EnzCheck Gelatinase/Collagenase Assay kit (Thermo Fisher
Scientific) and the SensoLyte 520 Generic MMP Assay kit
and SensoLyte 520 MMP Profiling kit (AnaSpec) according
to the manufacturers’ instructions. A list of the MMP-specific
fluorescence resonance energy transfer substrates used in the
MMP Profiling kit can be found in Table S2. Cell culture
supernatants for the gelatinase/collagenase assay were conditioned for 24 h in phenol red–free DMEM and stored at
−80°C until use. The MMP assays were performed with 50
µg mouse brain lysate per well.
tPA zymography and active tPA measurements
Hippocampal tPA activity was measured by in situ zymography with casein substrate, as previously described (Sachs et al.,
2007). In brief, fresh frozen,Tissue-TEK optimal cutting temperature (Sakura)–embedded brains were sections at 12 µm,
and sections 120 µm apart were used.The sections were overlaid with substrate, and the area lysed was quantified. tPA activity in conditioned cell culture medium was measured using
the active mouse tPA functional assay ELISA kit (Molecular
Innovations) according to the manufacturer’s instructions.
Phagocytosis assay
BV2 cells were plated on 24-well plates at a density of 50,000
cells per well in DMEM with 10% FBS. Cells were allowed
to settle on the plate for 1–2 h in a tissue culture incubator.
Fluorescent carboxyl microspheres (6 µm, flash red; Bangs
Laboratories Inc.) were opsonized for 30 min in 50% FBS
and PBS and then added to the BV2 cells at a concentration
of 10 beads per cell. Cells and beads were incubated for 1 h
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Western blotting
Tissue or cells were lysed on ice in RIPA buffer (50 mM TrisHCl, pH 7.4, 150 mM sodium chloride, 1% Nonidet P40,
1 mM EDTA, and 0.25 deoxycholic acid) with complete protease inhibitor (Roche), and the total protein concentration
was measured using a bicinchoninic assay kit (Thermo Fisher
Scientific). Lysates were run on 4–12% Bis-Tris gels (Thermo
Fisher Scientific) in 1× NuPage MES SDS running buffer
(Thermo Fisher Scientific). Proteins were transferred overnight onto nitrocellulose membranes in 20% (vol/vol) methanol in NuPage Transfer buffer (Thermo Fisher Scientific).
Membranes were blocked and then incubated in primary antibody overnight. Proteins were visualized and quantified on
an Odyssey infrared imaging system (LI-COR Biosciences).
The following antibodies were used: CT15 (Sisodia et al.,
1993), β-actin (Sigma-Aldrich), neuron-specific enolase (5E2;
Thermo Fisher Scientific), and IC16 (Hahn et al., 2011).
Mass spectrometric analysis of LA-1 in brain and plasma
C57BL/6 mice were injected i.p. with 500 µl of 50 µM LA-1.
At seven time points after injection (5 min, 15 min, 30 min,
1 h, 2 h, 4 h, and 8 h), mice were anesthetized, and EDTA
blood was collected by cardiac puncture. After blood collection, the mice were perfused with sterile PBS, and the brain
was collected and immediately frozen as hemibrains at −80°C.
Plasma was isolated from whole blood immediately by spinning at 1,000 g and stored at −80°C.Three animals were used
per time point. Right hemibrains were homogenized in 2 volumes of deionized water, using one volume of 0.5-mm glass
beads (Next Advance) in a Bullet Blender (Next Advance).
Brain homogenates and plasma samples were further diluted
in 50% and 20% methanol in acetonitrile. Samples were mixed
and clarified by centrifugation before analysis on a mass spectrometer (Qtrap 4000; Sciex). 10 µl of each sample was introduced into the mass spectrometer via a Dionex microcapillary
column (C18 5 µm 2.1 × 100 mm;Thermo Fisher Scientific).
Samples were eluted via 300 µl/min isocratic flow of 85%
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B (mobile phase A: 0.1 mM ammonium acetate in water; mobile phase B: 100% acetonitrile) for 2 min. Quantification
of LA-1 was performed using multiple reaction monitoring
transitions m/z 420.103-375.800 and m/z 420.103-230.000.
Method development, data acquisition, and data processing
were performed using Analyst 1.6.1 software (Sciex). LA-1
was quantified using untreated brain homogenates with
spiked-in LA-1 standards, and standard curves were generated
using cubic regression. Unknown LA-1 concentrations were
interpolated from the brain homogenate and plasma standard
curves using Prism 6 analysis software (GraphPad Software).
Stereotactic injection of Aβ
For stereotactic injection of Aβ, the mice were anesthetized to
full muscle relaxation with isoflurane (2.5–3.5% with oxygen, to
effect) and placed in a stereotaxic device. Surgeries were performed on heated pads, and body temperature was monitored
throughout the procedure. The skull was exposed, and a hole
was drilled into the skull at the injection site (coordinates
from bregma: A = −2 mm and L = −1.8 mm; from brain
surface: H = −2 mm) to target the hippocampus. A microsyringe (25 G) was used to infuse 1 µg of Aβ into the brain over
2 min. The cannula was left in place for an additional 3 min
and slowly withdrawn. The incision in the scalp was closed,
and the animals were allowed to recover.The animals received
0.05–0.1 µg/ml buprenorphine as directed for pain.
Flow cytometry and FACS
Flow cytometric analysis was performed on a Fortessa or
FACSCalibur FACS machine (BD). Standard staining was
performed. In brief, cells were washed three times with FACS
buffer and blocked using Fc-block CD16/32 antibody (BioLegend) for 15 min, followed by incubation with fluorescently labeled antibody for 30 min. Analysis was performed
using FlowJo software (version 9.2; Tree Star). PBMCs were
isolated by Ficoll centrifugation. The antibodies used were:
CD11b-PE antibody (BioLegend), CD162–Alexa Fluor 647
(BD), CD62L-FITC and CD18-PE (eBioscience), and CD54APC, CD14-Pe/Cy7, CD49d-FITC, CD11a-PE, CD11b–
eFluor 450 (all BioLegend). Sterile FACS to maintain CD11b
knockdown in CD11bkd BV2 cell lines was performed after
staining of CR3kd and control cells with CD11b-PE antibody,
as described in the previous paragraph. Cells were sorted on
a FACSAriaIII cell sorter (BD) for CD11blow-expressing cells,
defined by CD11b expression of <80% of control cells.Then,
cells were cultured as described in the Cell lines section.
Online supplemental material
Fig. S1 shows that MMP activity and expression is not
changed in CR3-deficient cells or mice. Fig. S2 shows that
LA-1 does not affect APP processing and does not change
the expression of vascular adhesion markers on PBMCs or
microglia.Table S1 contains the qPCR primer sequences, and
Table S2 shows the sequences of fluorescence resonance energy transfer substrates used in the MMP activity assays.
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Figure S1. MMP activity is not changed in CR3-deficient cells or mice. (A) Cell-free Aβ degradation assay in supernatants of adult WT and CR3−/− microglia with addition of protease inhibitors (PI). PI w/o, protease inhibitor cocktail lacking EDTA. (B) Cell-free assay in supernatants of control and CR3kd BV2
cells with addition of protease inhibitors. (A and B) Representative graphs of three independent experiments are shown. (C) Quantification of MMP2 and
MMP9 activity in conditioned medium of control and CR3kd BV2 cells. Combined data of two independent experiments are shown. (D) Quantification of total
MMP activity in cortical lysates of WT and CR3−/− mice. n = 9–11 individual mice. (E) Quantification of total MMP activity in cortical lysates of APP and APP/
CR3−/− mice. n = 6–7 individual mice. (F) Quantification of MMP profiling assay in cortical lysates of APP and APP/CR3−/− mice. n = 5 individual mice. (G)
qPCR analysis of MMP expression in mRNA from primary adult microglia. Primary microglia are from n = 7 individual mice. All groups are male and female
mice. Unpaired Student’s t test was used. *, P < 0.05; **, P < 0.01; ***, P < 0.001. All values are mean ± SEM.
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Figure S2. LA-1 treatment does not change APP processing or expression of vascular adhesion markers on PBMCs or microglia. (A) Representative Western blot showing APP processing in lysates and sAPPα levels in conditioned supernatants of APP-overexpressing Chinese hamster ovary cells
after LA-1 treatment. flAPP, full-length APP. (B) Aβ measurements in conditioned supernatants of APP-overexpressing Chinese hamster ovary cells after
LA-1 treatment. (C–F) Quantification of full-length APP and processing products after LA-1 treatment. (B–F) Data are combined from three independent
experiments. (G) qPCR analysis of MMP expression in mRNA from primary adult microglia. Primary microglia are from n = 7 individual mice. (H) Plasma
levels of LA-1 after a single injection quantified by mass spectrometry. n = 3 individual mice per time point, with only male mice. (I and J) Flow cytometric
quantification of vascular adhesion molecule expression on primary adult microglia (I) and PBMCs (J) isolated after 10 d of LA-1 injections. n = 5 individual
mice per group. All groups were male and female mice except for H. One-way ANOVA and Tukey’s posthoc test (B–F) or unpaired Student’s t test (G, I,
and J) was used. All values are mean ± SEM.
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Table S1. qPCR primer sequences
Gene
MMP2 for
MMP2 rev
MMP8 for
MMP8 rev
MMP9 for
MMP9 rev
MMP12 for
MMP12 rev
MMP13 for
MMP13 rev
MMP14 for
MMP14 rev
tPA for
tPA rev
IDE for
IDE rev
GAPDH for
GAPDH rev

Primer sequences (5′-3′)
CAAGTTCCCCGGCGATGTC
TTCTGGTCAAGGTCACCTGTC
TCTTCCTCCACACACAGCTTG
CTGCAACCATCGTGGCATTC
GAGACGGGTATCCCTTCGAC
TGACATGGGGCACCATTTGAG
GGGCTGCTCCCATGAATGAC
CCAGAGTTGAGTTGTCCAGTTG
CTTCTTCTTGTTGAGCTGGACTC
CTGTGGAGGTCACTGTAGACT
GCCTTGCCTGTCACTTGTAAA
CAGTATGGCTACCTACCTCCAG
AACGCAGACAACTTACCAACA
GTTCGCTGCAACTTCGGAC
GAACGATGCCTGGAGACTCTT
TTCCCTTACGTCGATGCCTTC
AGGTCGGTGTGAACGGATTTG
TGTAGACCATGTAGTTGAGGTCA

Abbreviations used: for, forward; IDE, insulin-degrading enzyme; rev, reverse.

Table S2. Sequence of FRET substrates and substrate specificity for the MMP profiling kit
Substrate
SB1
SB2
SB3
SB4
SB5
SB6
SB7
SB8
SB9
SB10
SB11
SB12
SB13
SB14
SB15
SB16

FRET peptide sequence

MMP specificity

QXL520-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-Lys(5-FAM)-NH2
QXL520-Pro-Leu-Ala-Leu-Trp-Ala-Arg-Lys(5-FAM)-NH2
QXL520-Pro-Leu-Gly-Cys(Me)-His-Ala-D-Arg-Lys(5-FAM)-NH2
5-FAM-Pro-Leu-Ala-Nva-Dap(QXL520)-Ala-Arg-NH2
5-FAM-Pro-Leu-Gly-Leu-Dap(QXL520)-Ala-Arg-NH2
QXL520-Pro-Leu-Gly-Met-Trp-Ser-Arg-Lys(5-FAM)-NH2
QXL520-Pro-Tyr-Ala-Tyr-Trp-Met-Arg-Lys(5-FAM)-NH2
QXL520-Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp-Lys(5-FAM)-NH2
QXL520-Arg-Pro-Leu-Ala-Leu-Trp-Arg-Lys(5-FAM)-NH2
QXL520-Pro-Leu-Ala-Tyr-Trp-Ala-Arg-Lys(5-FAM)-NH2
5-FAM-Pro-Cha-Gly-Nva-His-Ala-Dap-(QXL520)-NH2
5-FAM-Arg-Pro-Lys-Pro-Tyr-Ala-Nva-Trp-Met-Lys(QXL520)-NH2
5-FAM-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Lys-(QXL520)-NH2
QXL520-γ-Abu-Pro-Cha-Abu-Smc-His-Ala-Dab(5-FAM)-Ala-Lys-NH2
QXL520-γ-Abu-Pro-Gln-Gly-Leu-Dab-(5-FAM)-Ala-Lys-NH2
QXL520-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Trp-Lys(5-FAM)-NH2

13
1,7,8,12,13
1,2,8,9,12,13
1,2,7,8,12,13
1,2,7,8,12,13
2,13
7,12,13
7,12,13
1,2,7,8,12,13
13
1,2,8,12,13
1,2,3,12,13
3,12
1,2,3,7,8,9,12,14
1,2,7,8,12,13
12,13

Abbreviation used: FRET, fluorescence resonance energy transfer.
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